Angiogenesis inhibitor

bevaci –

zumab Avastin 100mg,

400mg soln for IV infusion after

dilution 15mg/kg once every 3wks with

carboplatin/paclitaxel

bevacizumab-awwb Mvasi 100mg, 400mg soln for IV infusion after dilution 15mg/kg every 3wks with carboplatin/paclitaxel until disease progression or unacceptable toxicity

bevacizumab-bvzr Zirabev 100mg, 400mg soln for IV infusion after dilution 15mg/kg every 3wks with carboplatin/paclitaxel

ramuci –

rumab Cyramza 10mg/mL soln for IV infusion after

dilution Exon 19 deletions or exon 21 mutations: 10mg/kg every 2wks with erlotinib. Disease progression: 10mg/kg on Day 1 of a 21-day cycle prior to docetaxel. Both: continue until disease progression or unacceptable toxicity.

Antimetabolites

gemcitabine Gemzar 200mg, 1g pwd for IV infusion after

reconstitution Give with cisplatin 100mg/m² administered on Day 1 after gemcitabine. 1000mg/m² on Days 1, 8, and 15 of each 28-day cycle; or 1250mg/m² on Days 1 and 8 of each 21-day cycle

Infugem 1200mg/120mL, 1300mg/130mL, 1400mg/140mL, 1500mg/150mL, 1600mg/160mL, 1700mg/170mL, 1800mg/180mL, 1900mg/190mL, 2000mg/200mL, 2200mg/220mL soln for IV infusion

metho –

trexate — 25mg/mL soln for IV, IM, intra-

arterial, or intrathecal

administration after

dilution See drug monograph and manufacturer’s full labeling

1g pwd for IV, IM, intra-

arterial, or intrathecal

administration after

dilution

Trexall 5mg, 7.5mg, 10mg, 15mg scored tabs

pemetrexed Alimta 100mg, 500mg pwd for IV infusion after

reconstitution and

dilution CrCl ≥45mL/min: 500mg/m² on Day 1 of each 21-day cycle. In combination with pembrolizumab and platinum chemotherapy: treat for 4 cycles; following platinum-based therapy completion, give pemetrexed with or without pembrolizumab until disease progression or unacceptable toxicity. In combination with cisplatin: treat for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Maintenance, recurrent NSCLC: continue until disease progression or unacceptable toxicity. Supplement with oral folic acid and IM vitamin B 12 one week prior to 1st pemetrexed dose, during treatment, and for 21 days after last dose. Pretreat with dexamethasone for 3 consecutive days, beginning the day before each pemetrexed dose.

Antimicrotubule agents

docetaxel Taxotere 20mg/mL soln for IV infusion after

dilution Infuse over 1hr once every 3wks. After platinum therapy failure: 75mg/m². Chemotherapy-naive: 75mg/m² followed by cisplatin (see full labeling).

paclitaxel — 6mg/mL soln for IV infusion after

dilution 135mg/m² IV plus cisplatin

every 3wks

paclitaxel [bound to albumin

(human)] Abraxane 100mg/

vial pwd for IV infusion after

reconstitution 100mg/m² on Days 1, 8, and 15 of each 21-day cycle with carboplatin

vinorelbine — 10mg/mL soln for IV inj after

dilution Monotherapy: 30mg/m² once

weekly. Combination therapy: 25mg/m²

on Days 1, 8, 15, and 22 of a 28-day cycle with cisplatin (100mg/m²) given on Day 1 of each 28-day cycle; or 30mg/m² once weekly with cisplatin (120mg/m²) given on Days 1 and 29, then every 6wks.

CTLA-4 Blocking Antibody

ipilimumab Yervoy 5mg/mL soln for IV infusion Metastatic NSCLC with PD-L1: 1mg/kg every 6wks with nivolumab 3mg/kg every 2wks. Metastatic or recurrent NSCLC: 1mg/kg every 6wks with nivolumab 360mg every 3wks and histology-based platinum doublet chemotherapy every 3wks for 2 cycles. Continue until disease progression, unacceptable toxicity, or up to 2yrs in patients without disease progression.

HUMAN EGFR INHIBITOR

necitumumab Portrazza 800mg/50mL soln for IV infusion after dilution 800mg on Days 1 and 8 of each 21-day cycle; continue until disease progression or unacceptable toxicity

Kinase Inhibitors

afatinib Gilotrif 20mg, 30mg, 40mg tabs 40mg once daily on empty stomach; continue until disease progression or unacceptable toxicity

alectinib Alecensa1 150mg caps 600mg twice daily until disease

progression or unacceptable

toxicity

brigatinib Alunbrig1 30mg, 90mg, 180mg tabs 90mg once daily for first 7 days, then increase to 180mg once daily; continue until disease progression or unacceptable toxicity.

capmatinib Tabrecta6 150mg, 200mg tabs 400mg twice daily.

ceritinib Zykadia1 150mg hard gel caps, tabs 450mg once daily with food until disease progression or unacceptable toxicity; discontinue if 150mg once daily with food not tolerated

crizotinib Xalkori1,5 200mg, 250mg caps 250mg twice daily until disease progression or unacceptable toxicity

dabrafenib Tafinlar4 50mg, 75mg caps In combination with trametinib: 150mg twice daily (approx. 12hrs apart); continue until disease recurrence or unacceptable toxicity

dacomitinib Vizimpro2 15mg, 30mg, 45mg tabs 45mg once daily until disease progression or unacceptable toxicity

erlotinib Tarceva2 25mg, 100mg, 150mg tabs 150mg once daily until disease progression or unacceptable toxicity

gefitinib Iressa2 250mg tabs 250mg once daily until disease progression or unacceptable toxicity

lorlatinib Lorbrena1 25mg, 100mg tabs 100mg once daily until disease progression or unacceptable toxicity

osimertinib Tagrisso2,3 40mg, 80mg tabs 80mg once daily until disease progression or unacceptable toxicity

selpercatinib Retevmo7 40mg, 80mg hard gel caps <50kg: 120mg twice daily (approx. every 12hrs). ≥50kg: 160mg twice daily (approx. every 12hrs). Continue until disease progression or unacceptable toxicity.

trametinib Mekinist4 0.5mg, 2mg tabs In combination with dabrafenib: 2mg once daily (approx. 24hrs apart); continue until disease recurrence or unacceptable toxicity

PD-1/PD-L1 Blocking Antibodies

atezolizumab Tecentriq 60mg/mL soln for IV infusion after

dilution Single agent: 840mg every 2wks, or 1200mg every 3wks, or 1680mg every 4wks. In combination with platinum-based chemotherapy: 1200mg every 3wks; after 4–6 cycles of chemotherapy completed, and if bevacizumab discontinued, give 840mg every 2wks, or 1200mg every 3wks, or 1680mg every 4wks. Continue until disease progression or unacceptable toxicity. In combination therapy: administer atezolizumab prior to chemotherapy and bevacizumab when given on the same day (see full labeling).

durvalumab Imfinzi 50mg/mL soln for IV infusion after

dilution 10mg/kg every 2wks until disease progression, unacceptable toxicity, or max 12mos

nivolumab Opdivo 10mg/mL soln for IV infusion after

dilution NSCLC with PD-L1: 3mg/kg every 2wks with ipilimumab (1mg/kg every 6wks); continue with ipilimumab until disease progression, unacceptable toxicity, or up to 2yrs in patients without disease progression. Metastatic or recurrent NSCLC: 360mg every 3wks with ipilimumab (1mg/kg every 6wks) and histology-based platinum doublet chemotherapy every 3wks (for 2 cycles only); continue with ipilimumab until disease progression, unacceptable toxicity, or up to 2yrs in patients without disease progression. NSCLC (single-agent): 240mg every 2wks or 480mg every 4wks until disease progression or unacceptable toxicity. Combination therapy: administer Opdivo first followed by ipilimumab, and/or platinum doublet chemotherapy on the same day.

pembrolizumab Keytruda 25mg/mL soln for IV infusion after

dilution 200mg every 3wks or 400mg every 6wks until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression. In combination with chemotherapy: give prior to chemotherapy when given on the same day (see full labeling).

Photosensitizing agent